Hikma Pharmaceuticals’ (HIK) “Buy” Rating Reiterated at Berenberg Bank

Berenberg Bank reiterated their buy rating on shares of Hikma Pharmaceuticals (LON:HIK) in a research note released on Thursday, MarketBeat Ratings reports. Berenberg Bank currently has a GBX 2,300 price objective on the stock.

A number of other brokerages have also recently issued reports on HIK. Peel Hunt restated a “buy” rating and issued a GBX 2,170 price objective on shares of Hikma Pharmaceuticals in a research note on Friday, November 7th. JPMorgan Chase & Co. lowered their target price on shares of Hikma Pharmaceuticals from GBX 2,500 to GBX 2,400 and set an “overweight” rating on the stock in a research note on Friday, November 7th. Jefferies Financial Group reissued a “buy” rating and issued a GBX 2,360 price target on shares of Hikma Pharmaceuticals in a research report on Friday, November 7th. Finally, Deutsche Bank Aktiengesellschaft decreased their price objective on Hikma Pharmaceuticals from GBX 2,500 to GBX 2,400 and set a “buy” rating on the stock in a report on Friday, January 9th. Five research analysts have rated the stock with a Buy rating, According to MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of GBX 2,326.

Hikma Pharmaceuticals Price Performance

LON HIK opened at GBX 1,554 on Thursday. The company has a market cap of £3.44 billion, a PE ratio of 9.31, a PEG ratio of 2.38 and a beta of 0.41. The company has a current ratio of 1.66, a quick ratio of 1.27 and a debt-to-equity ratio of 55.82. Hikma Pharmaceuticals has a 1 year low of GBX 1,482 and a 1 year high of GBX 2,360. The stock’s 50-day moving average price is GBX 1,551.34 and its two-hundred day moving average price is GBX 1,707.08.

Insider Transactions at Hikma Pharmaceuticals

In other Hikma Pharmaceuticals news, insider Mazen Darwazah acquired 315,000 shares of the business’s stock in a transaction on Thursday, November 6th. The stock was purchased at an average price of GBX 1,601 per share, for a total transaction of £5,043,150. Also, insider Said Darwazah acquired 70,000 shares of Hikma Pharmaceuticals stock in a transaction on Friday, November 7th. The stock was acquired at an average cost of GBX 1,541 per share, for a total transaction of £1,078,700. Insiders have acquired 448,214 shares of company stock valued at $712,497,058 in the last three months. 18.15% of the stock is owned by corporate insiders.

Hikma Pharmaceuticals Company Profile

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly. We are a trusted, reliable partner and dependable source of over 800+ (as of Feb 2025) high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe.